The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma

Linton, A. L.; Vardy, Janette; Clarke, Stephen; Zandwijk, Nico van

doi:10.1016/j.critrevonc.2012.03.001

Cited by 46 publications

(32 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further analyses are warranted on Australian data to investigate more comprehensively the different speed of incidence rate changes by age group, including sensitivity analyses of age group categories. In our study, taking into account latency period estimates for asbestos exposure, 46 younger people with malignant mesothelioma are likely to have developed it from highly elevated levels of asbestos exposure through the manufacturing and installation of asbestos-containing products, neighbourhood exposure as children or asbestos mining and production. Bans on the use of asbestos-containing products and asbestos mining implemented over time will have changed the disease trajectory for these younger age groups.…”

confidence: 99%

Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972–2009

Soeberg

Creighton

Currow

et al. 2016

Australian and New Zealand Journal of Public Health

Self Cite

View full text Add to dashboard Cite

Introduction: Malignant pleural mesothelioma (MPM) and malignant peritoneal mesothelioma (MPeM) are often grouped together in descriptive epidemiological analyses, resulting in limited understanding of epidemiological patterns for these tumour types. Methods:We studied patterns in the incidence, mortality and survival of people diagnosed with MPM (n=4,076) and MPeM (n=293) in New South Wales (NSW), Australia, 1972Australia, -2009. We also calculated 5-year relative survival for people diagnosed 1972-2006 followed up to 2007. We assessed patterns for each tumour type and histological subtype and, where possible, by combination of these categories.Results: Annual MPM cases steadily increased over time (n=208 in 2009). There was an increasing trend in the MPM age-standardised incidence rate from 1972 up to 1994. This rate increase has levelled off in the past 10 years. Since 1999, 11 cases of MPeM were diagnosed each year, on average. Five-year relative survival remained stable for MPM and MPeM. However, 5-year relative survival in 2002-2006 was substantially higher for people with MPM epithelioid histological subtype (11.7% .2%]) compared to all other non-epithelioid histological subtypes (6.9% [95%CI 5.0-9.1%]), a 70% difference. Survival was also greater for women with .4%]) compared to men (7.0% [95%CI 5.1-9.2%]).Interpretation: MPM incidence rates have stabilised since the mid-1990s, suggesting that maximum incidence levels have been reached. When more up-to-date data are available, survival estimates should be reanalysed to include people likely to benefit from the wide introduction of combination chemotherapy in 2007, including pemetrexed.

show abstract

confidence: 99%

Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972–2009

Soeberg

Creighton

Currow

et al. 2016

Australian and New Zealand Journal of Public Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…Current therapies, with the exception of surgery in very early disease states, are not curative [12]. The most recent statistics on MM mortality show that there were 2704 deaths in the USA in 2005 with little evidence that rates are declining [13]. Although asbestos use has been restricted in many western countries, it is still mined in Russia, China, Canada, Brazil, Kazakhstan and Zimbabwe [13,14].…”

Section: Asbestos-related Diseasesmentioning

confidence: 99%

“…The most recent statistics on MM mortality show that there were 2704 deaths in the USA in 2005 with little evidence that rates are declining [13]. Although asbestos use has been restricted in many western countries, it is still mined in Russia, China, Canada, Brazil, Kazakhstan and Zimbabwe [13,14]. It has been estimated approximately 125 million people are exposed to asbestos globally within their place of work, often in third world countries that do not have strictly regulated workplace safety controls.…”

Section: Asbestos-related Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure

et al. 2015

View full text Add to dashboard Cite

Asbestos exposure is known to cause lung cancer and mesothelioma and its health and economic impacts have been well documented. The exceptionally long latency periods of most asbestos-related diseases have hampered preventative and precautionary steps thus far. We aimed to summarize the state of knowledge on biomarkers of response to asbestos exposure. Asbestos is not present in human biological fluids; rather it is inhaled and trapped in lung tissue. Biomarkers of response, which reflect a change in biologic function in response to asbestos exposure, are analyzed. Several classes of molecules have been studied and evaluated for their potential utility as biomarkers of asbestos exposure. These studies range from small molecule oxidative stress biomarkers to proteins involved in immune responses.

show abstract

“…However, the long latency period of 20 -40 years prior to the development of the disease explains the recent steady increase in incidence of new cases. This currently represents about 3000 new cases per year in the US, [1] and corresponds to the peak use of asbestos in the last century [2][3][4]. In 1989, the US Environmental Protection Agency banned most asbestos-containing products.…”

Section: Introductionmentioning

confidence: 99%

Malignant Pleural Mesothelioma: Treatment Options and Novel Therapies

Martin¹,

Zwischenberger²,

Fabian³

2014

JCT

View full text Add to dashboard Cite

Malignant pleural mesothelioma is a rare primary tumor rising from the pleura and is associated with exposure to asbestos fibers. Mesothelioma is a locally aggressive disease that usually presents at an advanced stage and has a median overall survival of 1 year. Treatment options rarely result in cure of disease and range from trimodality treatment, including chemotherapy, radiation, and surgery, to supportive care. In patients with limited local disease and good functional status, trimodality treatment with extra-pleural pneumonectomy, chemotherapy, and radiation is frequently employed. Best supportive care should be instituted for patients with metastatic disease and poor functional status. Palliative therapy focuses on control of pleural effusions with drainage techniques and pain with radiation therapy. Novel therapies are showing promise, including photodynamic therapy, immunotherapy, and molecular targeted therapy.

show abstract

The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma

Cited by 46 publications

References 101 publications

Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972–2009

Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972–2009

Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure

Malignant Pleural Mesothelioma: Treatment Options and Novel Therapies

Contact Info

Product

Resources

About